Sie sind nicht angemeldet.

No Upcoming lectures

Karl-Ludwig Laugwitz Profile Page
Karl-Ludwig Laugwitz
Research Area: Molecular Medicine|*|Cardiovascular Research
Research Topic: Cardiovascular Development; Transcriptional Regulation; Human ESC- and iPSC Technology; Stem Cell Therapy
Research Summary: The purification, renewal and differentiation of native cardiac progenitors would form a mechanistic underpinning for unraveling steps for both cardiac lineage formation and regeneration, and their links to forms of congenital and adult cardiac diseases. Further understanding of molecular cascades that are active during cardiac formation are proving useful for the identification and manipulation of embryonic and adult cardiac stem/progenitor cells that offer opportunities for the treatment of adult and congenital heart disease. Lineage tracing studies documented that the LIM-homeodomain transcription factor Islet-1 (Isl1) represents an embryonic marker for a genetically distinct population of undifferentiated master heart progenitors that give rise to all of the major muscle and non-muscle cell lineages of the heart. Utilizing ESCs and iPSCs that harbor knock-ins of reporter genes under the expression control of the genomic isl1 locus allows the isolation of Isl1+ cardiac progenitors from mouse and human pluripotent stem cell systems during in vitro cardiogenesis. These genetic systems should allow the rapid and direct identification of signaling pathways which guide the formation, renewal, and diversification of ISL1+ heart progenitors into distinct heart cell lineages, and forms a biological foundation for tissue engineering of specific heart components.
Lab website:
Selected Publications: 1. Chien KR, Moretti A & Laugwitz K-L (2004). ES cells to the Rescue. Science 306: 239-240.

2. Laugwitz, K-L, Moretti, A, Caron L, Nakano A & Chien KR (2008). Islet1 cardiovascular progenitors: a single source for heart lineages? Development 135, 193-205.

3. Laugwitz K-L, Moretti A, Lam J, Gruber P, Yinhong Chen, Woodard S, Lin L-Z, Cai C-L, Lu M, Reth M, Platoshyn O, Yuan J, Evans S & Chien KR (2005). Postnatal Isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature 433: 647-653.

4. Moretti A, Caron, L, Nakano, A, Lam, JT, Chen, Y, Qyang, Y, Sasaki, M, Yunfu, S, Evans, S, Laugwitz, K-L & Chien KR (2006). Multipotent embryonic Isl1+ progenitor cells lead to cardiac, smooth muscle, and endothelial cell diversification. Cell 127: 1151-1166.

5. Qyang Y, Martin-Puig S, Ghiravuri M, Chen S, Xu H, Bu L, Jiang X, Granger A, Moretti A, Caron L, Clarke J, Taketo MM, Laugwitz K-L, Moon R, Gruber P, Ding S and Chien KR (2007). The in vivo renewal and differentiation of Isl1+ cardiovascular progenitors is controlled by a Wnt/beta-catenin pathway. Cell Stem Cell 1, 165-179.

6. Moretti A, Jung C, Bellin M, Nhan T-M, Takashima Y, Bernshausen A, Schiemann M, Frei E-M, Moosmang S, Smith AG, Lam JT & Laugwitz, K.-L (2010). Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB Journal 24, 700-711.

7. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flügel L, Dorn T, Ph.D., Sinnecker D, Höhnke C, Seyfarth M, Hofmann F, Schömig A & Laugwitz K-L (2010). Modeling LQT1 syndrome in cardiac myocytes from patient-specific induced pluripotent stem cells. (in Revision).